- Expects continued strong financial and operating momentum in 2021, forecasting total revenues of $2 billion at the midpoint and Adjusted EBITDA of $780 million at the midpoint, both increases year-over-year
- Reports preliminary 2020 total revenues of $1.55 billion at the midpoint and Adjusted EBITDA of $635 million at the midpoint, both at or above prior guidance given in November 2020
PRELIMINARY 2020 FINANCIAL RESULTS (Unaudited)
The Company is providing the following preliminary, unaudited financial results for full year 2020.
| (in millions) | PRELIMINARY RESULTS (As of 1/10/2021) | PRIOR 2020 GUIDANCE (As of 11/5/2020) |
| Total Revenues | $1,545 - $1,555 | $1,520 - $1,580 |
| Net Income | $295 - $310 | $255 - $285 |
| Adjusted EBITDA (1) | $625 - $645 | $575 - $615 |
| Adjusted Net Income (1) | $415 - $430 | $375 - $405 |
2021 FINANCIAL FORECAST
The Company is providing the following forecast of selected financial metrics for full year 2021.
(in millions) | FULL YEAR 2021 (As of 1/10/2021) |
| Total Revenues | $1,950 - $2,050 |
| Adjusted EBITDA (1) | $750 - $810 |
| Adjusted Net Income (1) | $475 -- $525 |
| Product/Service Level Revenue | |
| • Anthrax Vaccines | $280 -- $310 |
| • ACAM2000 | $185 -- $205 |
| • NARCAN® Nasal Spray | $305 -- $325 |
| • CDMO Services | $925 -- $965 |
| • Other Products and Contracts and Grants | $220 -- $240 |
PRESENTATION WEBCAST
The Company will provide an update on the current business and discuss preliminary 2020 financial results, the forecast and corporate goals for 2021, and long-term goals during its presentation at the 39th Annual J.P. Morgan Healthcare Conference on January 11, 2021 at 8:20 AM Eastern time.
A live webcast of the presentation can be accessed through Emergent’s website. An on-demand replay of the webcast can also be accessed in the investors section after the presentation has concluded.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.